NCT05983965 is a Phase 1 clinical trial of Tazemetostat in T-cell Lymphoma, sponsored by University of Alabama at Birmingham.

Who is sponsoring NCT05983965?

NCT05983965 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT05983965?

Interventions in NCT05983965: Tazemetostat.

What condition does NCT05983965 study?

NCT05983965 studies T-cell Lymphoma.

Is NCT05983965 still recruiting?

NCT05983965 is currently terminated. Last updated 17 April 2026.

Last reviewed 2026-04-17 · How we verify

NCT05983965

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Tazemetostat in Lymphoid Malignancies

Terminated Phase 1 Last updated 17 April 2026

What this trial tests

Phase 1 trial testing Tazemetostat in T-cell Lymphoma in 6 participants. Terminated before completion.

Timeline

5 September 2024

Primary endpoint
6 March 2026

6 March 2026

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	5 September 2024
Primary completion	6 March 2026
Estimated completion	6 March 2026
Sites	1 location across United States

Drugs / interventions tested

Tazemetostat (tazemetostat) — full drug profile →

Conditions studied

T-cell Lymphoma — all drugs for T-cell Lymphoma →

Sponsor

University of Alabama at Birmingham

Who can join

18 and older, any sex, with T-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tazemetostat is an oral EZH2 inhibitor which has been FDA approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment option. We propose a study to evaluate the safety of tazemetostat in relapsed / refractory peripheral T-cell lymphoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic targeting potential of the protein lysine and arginine methyltransferases to reverse cancer chemoresistance.
Micallef I, Fenech K, Baron B. · · 2024 · cited 5× · PMID 39703687 · DOI 10.3389/fmolb.2024.1455415
Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities.
Wozniak M, Czyz M. · · 2025 · cited 2× · PMID 39776536 · DOI 10.1177/17588359241306026

Verify or expand the search:

Other trials of Tazemetostat

Trials testing the same drug.

NCT06575686 — Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · Phase 2 · suspended
NCT06692452 — Tazemetostat Plus CHOP in 1L T-cell Lymphoma · Phase 2 · withdrawn
NCT06242834 — Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggres · Phase 2 · active not recruiting
NCT05151588 — Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma · Phase 2 · not yet recruiting
NCT05407441 — Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors · Phase 1, PHASE2 · active not recruiting

Other recruiting trials for T-cell Lymphoma

Currently open trials in the same condition.

NCT07388563 — Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma · Phase 1 · recruiting
NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
NCT06550427 — Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing · recruiting
NCT04234048 — Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma · Phase 1 · recruiting
NCT06224049 — Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T · EARLY_PHASE1 · recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05983965 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 17 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05983965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing